



OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE
HEALTH AFFAIRS

16401 EAST CENTRETECH PARKWAY
AURORA, COLORADO 80011-9066

TRICARE
MANAGEMENT ACTIVITY

MB&RB

**CHANGE 51
6010.57-M
JUNE 30, 2011**

**PUBLICATIONS SYSTEM CHANGE TRANSMITTAL
FOR
TRICARE POLICY MANUAL (TPM), FEBRUARY 2008**

The TRICARE Management Activity has authorized the following addition(s)/revision(s).

CHANGE TITLE: EVOLVING PRACTICES - JUNE 2011

CONREQ: 15403

PAGE CHANGE(S): See page 2.

SUMMARY OF CHANGE(S): See page 3

EFFECTIVE AND IMPLEMENTATION DATE: As indicated, otherwise upon direction of the Contracting Officer.

**Ann N. Fazzini
Chief, Medical Benefits and
Reimbursement Branch**

**ATTACHMENT(S): 32 PAGE(S)
DISTRIBUTION: 6010.57-M**

CHANGE 51
6010.57-M
JUNE 30, 2011

REMOVE PAGE(S)

CHAPTER 1

Section 3.1, pages 1 and 2

Section 12.1, pages 1 and 2

CHAPTER 4

Section 6.1, pages 1 - 3

Section 9.2, page 1

CHAPTER 5

Section 1.1, pages 7 and 8

CHAPTER 7

Section 27.1, pages 1 and 2

APPENDIX A

pages 3 - 22

INSERT PAGE(S)

Section 3.1, pages 1 and 2

Section 12.1, pages 1 and 2

Section 6.1, pages 1 - 3

Section 9.2, page 1

Section 1.1, pages 7 and 8

Section 27.1, pages 1 and 2

pages 3 - 22

SUMMARY OF CHANGES

CHAPTER 1

1. Section 3.1. Added extracorporeal photopheresis is proven and may be considered for cost-sharing when the diagnosis is Bronchiolitis Obliterans Syndrome (BOS).
2. Section 12.1. Added XSTOP Interspinous Process Decompression System to the EXCLUSIONS as it is unproven.

CHAPTER 4

3. Section 6.1.
 - a. Removed procedures from the EXCLUSIONS list that were previously determined to be proven.
 - b. Added CPT Codes and HCPCS code for the XSTOP Interspinous Process Decompression System which remains unproven and listed as an exclusion.
 - c. Repositioned and clarified existing language for hip arthroscopy in the EXCLUSION listing.
4. Section 9.2. Added coverage for extracorporeal photopheresis for the treatment of Bronchiolitis Obliterans Syndrome (BOS) that is refractory to immunosuppressive drug treatment may be considered for cost-sharing under the rare disease policy.

CHAPTER 5

5. Section 1.1. Spelled out acronym CAD as "Computer-Aided Detection" since CAD, meaning Coronary Artery Disease is used in the same section.

CHAPTER 7

6. Section 27.1. Botulinum toxin A injections to treat spasticity in flexor muscles of the elbow, wrist, and finger (upper limb spasticity) in adults is proven and added for coverage, effective March 9, 2010.

APPENDIX A

7. Acronym added.

